22nd Mar 2023 07:05
22 March 2023
BIOPHARMA CREDIT PLC
(THE "COMPANY")
ORDINARY AND SPECIAL DIVIDEND DECLARATION
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 31 December 2022 of $0.03329105 per ordinary share, payable on 28 April 2023 to ordinary shareholders on the register as at 31 March 2023. The ex-dividend date will be 30 March 2023. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest, which will result in a reduction in the corporation tax payable by the Company.
The $0.03329105 dividend comprises an ordinary dividend of $0.0175 and a special dividend of $0.01579105. The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 31 March 2023 (the "Election Date").
Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24